17/11/2020 (Agence Europe) – As announced the day before, the European Commission approved on Tuesday 17 November an early purchase agreement for the candidate vaccine developed by the German company CureVac (see EUROPE B12602A2). The agreement provides for the initial purchase of 225 million doses, with the possibility of adding a further 180 million doses. The Commission also pointed out that it had finalised exploratory discussions with the American company Moderna on 160 million...